Sep 06, 2022 8:00am EDT MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022
Aug 30, 2022 7:00am EDT MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids
Aug 22, 2022 8:00am EDT MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 02, 2022 8:00am EDT MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)
Jul 18, 2022 8:00am EDT MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer
Jun 14, 2022 8:14am EDT MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies
May 19, 2022 8:45am EDT MAIA Biotechnology, Inc. Establishes Wholly Owned Subsidiaries in Romania and Australia to Support Global Development of THIO
Apr 26, 2022 8:37am EDT MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC)
